tiprankstipranks
Advertisement
Advertisement

AU:RMD Stock Latest News

ResMed Updates CDI Count Amid Routine Share Transfers, Issuances and Buybacks
Company AnnouncementsResMed Updates CDI Count Amid Routine Share Transfers, Issuances and Buybacks
15h ago
ResMed Files March 2026 Quarterly Report Detailing Capital Structure and Compliance Status
PremiumCompany Announcements
ResMed Files March 2026 Quarterly Report Detailing Capital Structure and Compliance Status
15h ago
ResMed price target lowered to $225 from $254 at Baird
PremiumThe Fly
ResMed price target lowered to $225 from $254 at Baird
3d ago
RMD
ResMed price target lowered to $235 from $265 at Stifel
PremiumThe Fly
ResMed price target lowered to $235 from $265 at Stifel
3d ago
RMD
Analyst Brandon Vazquez Reiterates Buy on ResMed Amid Solid Execution, Margin Expansion, and Attractive Valuation Despite Near-Term Headwinds
PremiumRatings
Analyst Brandon Vazquez Reiterates Buy on ResMed Amid Solid Execution, Margin Expansion, and Attractive Valuation Despite Near-Term Headwinds
3d ago
RMD
Closing Bell Movers: Apple higher after stronger than expected guidance
PremiumThe FlyClosing Bell Movers: Apple higher after stronger than expected guidance
4d ago
CLX
DLB
ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed
Premium
The Fly
ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed
4d ago
RMD
ResMed reports Q3 EPS $2.86, consensus $2.72
Premium
The Fly
ResMed reports Q3 EPS $2.86, consensus $2.72
4d ago
RMD
Notable companies reporting after market close
PremiumThe Fly
Notable companies reporting after market close
4d ago
CLX
MTZ
ResMed price target lowered to $290 from $302 at KeyBanc
PremiumThe Fly
ResMed price target lowered to $290 from $302 at KeyBanc
7d ago
RMD
ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks
PremiumRatings
ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks
17d ago
RMD
ResMed initiated with an Overweight at JPMorgan
PremiumThe Fly
ResMed initiated with an Overweight at JPMorgan
19d ago
RMD
ResMed price target lowered to $255 from $300 at Evercore ISI
PremiumThe FlyResMed price target lowered to $255 from $300 at Evercore ISI
21d ago
RMD
ResMed price target lowered to $340 from $345 at Citi
Premium
The Fly
ResMed price target lowered to $340 from $345 at Citi
25d ago
RMD
ResMed CEO Michael Farrell Plans Additional Insider Sale Under Rule 144
Premium
Company Announcements
ResMed CEO Michael Farrell Plans Additional Insider Sale Under Rule 144
27d ago
ResMed Adjusts CDI and Share Balances Amid Transfers, Equity Issuance and Buybacks
PremiumCompany Announcements
ResMed Adjusts CDI and Share Balances Amid Transfers, Equity Issuance and Buybacks
28d ago
ResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144
PremiumCompany Announcements
ResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144
28d ago
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144
PremiumCompany Announcements
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144
28d ago
Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
PremiumRatings
Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
1M ago
RMD
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan
PremiumCompany AnnouncementsResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan
2M ago
ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144
Premium
Company Announcements
ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144
2M ago
ResMed Updates CDI Count Amid Cross-Market Transfers and Buybacks
Premium
Company Announcements
ResMed Updates CDI Count Amid Cross-Market Transfers and Buybacks
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >